Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Avacta Group plc ( (GB:AVCT) ) has provided an announcement.
Avacta Group PLC has issued over six million new ordinary shares to settle a portion of its unsecured convertible bond, reducing the bond’s principal by £2.55 million. This strategic move aligns with the company’s efforts to become a pure play biotechnology firm, focusing on drug development while exploring financing options such as divesting its Diagnostics Division and potentially pursuing a NASDAQ dual listing.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company specializing in targeted oncology drugs. Utilizing their proprietary pre|CISION® platform, they focus on developing cancer therapies that are highly potent and tumor-specific, offering advantages over traditional treatments.
YTD Price Performance: 2.00%
Average Trading Volume: 1,541,666
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £186.6M
Find detailed analytics on AVCT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue